Related Experiment Videos
Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization
D D Hiraki1, K See-Tho, E Filvaroff
1Department of Pathology, Stanford University School of Medicine, California.
Human Immunology
|July 1, 1994
Summary
Researchers engineered a soluble form of HLA-B7 (sB7) for consistent antigen production. This soluble HLA-B7 protein is valuable for further immunological studies and animal model tolerogenicity testing.
Area of Science:
- Immunology
- Molecular Biology
- Protein Engineering
Background:
- Human Leukocyte Antigen (HLA) class I molecules play crucial roles in immune responses.
- Engineering soluble forms of HLA molecules can facilitate their study and therapeutic applications.
Purpose of the Study:
- To engineer and characterize a soluble, secreted form of HLA-B7 (sB7).
- To assess the potential of sB7 as a tool for immunological research and tolerogenicity studies.
Main Methods:
- Genetic engineering of the HLA-B7 gene to replace transmembrane and cytoplasmic domains with a C-terminal peptide.
- Transfection of modified gene (gsB7) into cell lines (J27.2, C1R).
- Analysis of secreted protein (sB7) using size fractionation, SDS-PAGE, Northern blots, and PCR.
Main Results:
- Engineered gsB7 gene produced secreted sB7 protein, recognized serologically as B7.
- sB7 existed as a 55 kD alpha-chain-beta 2m heteroduplex and a 120 kD dimer.
- SDS-PAGE revealed sB7 heavy chain heterogeneity due to carboxyl terminal variations.
- sB7 was not detected on cell surfaces or inhibitory to cytotoxic T lymphocytes (CTLs).
Conclusions:
- A soluble, secreted form of HLA-B7 (sB7) was successfully produced.
- The sB7 protein exists in monomeric and dimeric forms.
- This engineered sB7 provides a consistent source for studying soluble class I antigens and for tolerogenicity assessments.